Arcus Biosciences, Inc. RCUS
$19.10
-19.58%
at last close
Market Cap$3.02 billion
P/E Ratio—
Div Yield—
Volume4.65M
52-Week Range
$11.68$31.73
Analyst Ratings
- Consensus
- Buy — 10 Buy · 3 Hold · 0 Sell (13 analysts)
- Avg. Price Target
- $39.00 (+104.2% upside)
Key Stats
- Today's Range
- $18.98 – $24.47
- 50-Day Range
- $18.98 – $31.58
- 52-Week Range
- $11.68 – $31.73
- Volume
- 4.65 million shs
- Average Volume
- 1.97 million shs
- Market Cap
- $3.02 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.06%
- Days to Cover
- 1.00
About Arcus Biosciences, Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
Related Stocks
Compare head-to-head: RCUS vs LLY·RCUS vs JNJ·RCUS vs ABBV·RCUS vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.